AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
SCYNEXIS, Inc.
Video analysis: SCYX
All videosNo video analysis for this stock yet. Request one from our team.
News: SCYX
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D.
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average – Here’s What Happened
SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.78 and traded as high as $5.35. SCYNEXIS shares last traded at $5.15, with a volume of 33,068 shares traded. Wall Street Analysts Forecast Growth A
SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director's employment with the Company, as a material inducement to the employee's acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200 Day Moving Average – Time to Sell?
SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $5.89 and traded as low as $4.41. SCYNEXIS shares last traded at $5.07, with a volume of 432,304 shares. Analysts Set New Price Targets
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.
